From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Thu, 30 Apr 2020 13:31:50 +0000

To: Julie.Steenhuysen@thomsonreuters.com

Ce: Greg Folkersf CYC)

Subject: FW: Fauci says leak concerns fueled his White House revelation of Gilead drug
results

Julie:

You did a good job in reporting our conversation last night. Thanks.
Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: f __\ (0,

FAX: (301) 496-4409

E-mail:f |
The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

 

From: Folkers, Greg (NIH/NIAID) [EJ[ >

Sent: Thursday, April 30, 2020 8:59 AM

To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID
OD AM <NIAIDODAM @niaid.nih.gov>

Subject: Fauci says leak concerns fueled his White House revelation of Gilead drug results

Health News
April 30, 2020 / 1:07 AM / Updated 4 hours ago

Fauci says leak concerns fueled his White
House revelation of Gilead drug results

Julie Steenhuysen
5 Min Read

CHICAGO (Reuters) - Concerns over leaks compelled the top U.S. infectious disease official to reveal data
on Gilead Sciences Inc’s experimental drug remdesivir, the first in a scientifically rigorous clinical trial to
show benefit in treating COVID-19.
